Abbott Q3 Revenue Rises 14.5% to $13.01 Billion
Abbott Laboratories reported Q3 2026 revenue of $13.01B, up 14.5% YoY, slightly above estimates. Adjusted EPS matched expectations at $1.42, while GAAP EPS fell to $0.53. Diagnostics revenue surged 46.7% due to Exact Sciences acquisition. Abbott plans to spin off its Nutrition business by late 2027 and narrowed its full-year adjusted EPS guidance to $5.50–$5.55.
How this was made

The 30-second read
Why it matters
The earnings beat and guidance stability are likely to generate buying interest, though GAAP EPS weakness may cause some caution.
Market read
Abbott's earnings surprise provides a clear short-term trading catalyst for the stock and its sector.
What to watch
Nutrition spin‑off plans may introduce execution risk and dilute focus on core businesses.
Background
Abbott Laboratories is a diversified healthcare company with segments in diagnostics, medical devices, nutrition, and pharmaceuticals.
Ticker impact
Abbott reported Q3 2026 revenue of $13.01B, up 14.5% YoY, beating estimates and provided updated EPS guidance.
potential upside as market prices in the revenue beat and unchanged full-year EPS outlook
Large-cap earnings surprise with a solid beat on revenue and maintained guidance typically drives short-term buying pressure.
Market effects
Strong diagnostics growth may boost the broader healthcare equipment sector.
U.S. healthcare stocks could see modest gains following Abbott's beat.
Limited to investors tracking large-cap U.S. pharma and diagnostics companies.
Counterpoint
GAAP EPS decline and modest guidance narrowing could signal underlying margin pressure.
Key entities
- companyAbbott Laboratories
U.S.-listed healthcare conglomerate reporting Q3 2026 results.




